🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A welcome reception and resource fair sponsored by GAPSA brought together new graduate and professional students from all 12 schools. The event introduced students to multiple campus groups and University leaders, including President Liz Magill. bit.ly/3AHvkLd

I met some amazing people at the Peptide GRS and I can’t wait to see where their careers take them!

Especially Hoang-Anh T Phan, Ph.D. career 👀 don’t forget to “Vote HAP”

The University will raise the minimum Ph.D. stipend to $38,000, beginning in the coming 2023-24 academic year, the largest one-time increase in Penn’s history. bit.ly/3FmGR4Z

Congrats Alison and Hoang-Anh! This award "Recognizes students who have significantly impacted or extensively contributed to graduate and professional student life at Penn through outstanding service involvement in student life programs, initiatives, or organizations." Yup. 👏👏

Congrats to Alison Knasin (Ph.D. in chemistry) and Hoang Anh Phan (Ph.D. in chemistry) who received 2022-23 Graduate Student Leadership Awards for their service and lasting contributions to graduate student life at Penn. bit.ly/3NTk46Q Penn Chemistry

I am honored and humbled to be recognized for my service and contributions to graduate student life at Penn. Congratulations to my fellow awardees and thanks to all who have mentored/inspired me along the way!

BREAKING NEWS The 2023 #NobelPrize in Physiology or Medicine has been awarded to Katalin Karikó and Drew Weissman for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19.

Katalin Karikó and Drew Weissman – awarded the 2023 #NobelPrize in Physiology or Medicine – discovered that base-modified mRNA can be used to block activation of inflammatory reactions and increase protein production when mRNA is delivered to cells.

Katalin Karikó and Drew Weissman, Penn’s historic mRNA vaccine research team, win 2023 The Nobel Prize in Medicine bit.ly/48BswPR #nobelprize

New preprint alert! Our lab has captured the first glimpse of how #TAPBPR selects #antigens for #MHCI presentation. Focusing on a high-fidelity #immune checkpoint, our structural insights guide new approaches to #vaccine design and #cancer #immunotherapy. tinyurl.com/tuuwjjh4

📸 Snapshots from #NPAW2024 last week! To all our postdoctoral fellows at Children's Hospital: THANK YOU! 🙌 And a special thanks to our Office of Academic Training & Outreach Programs + CHOP Postdoc Alliance for a fun & educational roster of events!

Proud to unveil TRACER-I, a de novo protein platform developed through 5 years of collaboration with Possu Huang Lab. By recognizing diverse #MHC-I antigens (cancer, autoimmune & pathogenic), we're paving the way for more accessible immunotherapies. Congratulations to

1/ In two back-to-back papers, we present our de novo TRACeR platform for targeting MHC-I and MHC-II antigens TRACeR for MHC-I: go.nature.com/4gcLzn5 TRACeR for MHC-II: go.nature.com/4gj5OQk Haotian Du Jingjia Liu SgourakisLab Stanford Biosciences Penn Allergy and Immunology CHOP Research

Stanford Chemistry CHOP Research Penn Medicine Scripps Research Stanford Bioengineering Stanford Cancer Institute Chan Zuckerberg Biohub Network Possu Huang Lab Haotian Du SgourakisLab .Children's Hospital, Stanford University researchers reveal and refine new immunotherapy platform with increased potential to target cancer cells #NBTintheNews chop.edu/news/childrens…

Ready-to-load MHC-I Nanoparticles for High-throughput T cell Screening Studies biorxiv.org/cgi/content/sh… #biorxiv_immuno

Grateful to contribute a small part to this exciting effort in developing a new protein-based, MHC-targeting immunotherapy platform. Congrats again to lead author Haotian Du and all the incredible co-authors at Children's Hospital, Penn, and Stanford University!

Excited to share my latest first-author manuscript, now available as a preprint on bioRxiv Immunology! We introduce VLP-Open HLA, a new protein-based nanoparticle platform for T-cell screening studies, leveraging SpyTag/SpyCatcher bioconjugation chemistry and engineered open MHC-I!